GenBody wins bid for Korean Red Cross Blood Services procurement project: “Accelerating global market expansion”

- "Anemia measuring device 'Hemonitor H1' earns recognition for excellence"

- "Additional contracts with international Red Cross blood centers anticipated in the future" 

THE BIO | 성재준 기자 | sjj@thebionews.net | 2024.10.10 12:50

GenBody, a company specializing in diagnostic kits, reported on October 10 that it has secured the Korean Red Cross Blood Services (KRCBS) procurement project by winning a competitive bid against top Korean and international companies.

Through this successful bid, GenBody will provide 604 'Hemonitor H1' devices along with approximately 8.6 million disposable 'cuvettes' to blood donor centers and buses operated by the Korean Red Cross over the next three years.

The Hemonitor H1 is a device that quickly measures hemoglobin levels in blood, playing a crucial role in assessing blood donation eligibility and managing anemia.

Assessing donor eligibility is vital for maintaining the safety and efficiency of the blood supply, ensuring that donors are healthy and that recipients receive safe transfusions. In particular, accurately measuring hemoglobin levels is an essential step in screening for anemia and securing a safe blood supply.

The Hemonitor H1 is a device that simplifies these procedures. It features a compact design and runs on both battery and USB power, making it highly portable. The device offers laboratory-level accuracy with automatic calibration, ensuring ease of use. It delivers results in as little as 3 seconds from a small fingertip capillary blood sample of 8~10 µL, enabling quick and efficient diagnosis.

Additionally, the cuvette, a disposable consumable used with the Hemonitor H1, functions as a reagent for blood collection and testing. As the demand for cuvettes rises with the number of blood donations, steady sales are anticipated.

GenBody has already completed or is in the process of registering the Hemonitor H1 in several countries, including Thailand, Indonesia, Malaysia, Singapore, Taiwan, Peru, Saudi Arabia, and Kenya. This is expected to lead to additional contracts with overseas Red Cross blood centers in addition to domestic agreements. Furthermore, the device is anticipated to expand its application to other medical fields, such as obstetrics and gynecology and family medicine, both in Korea and internationally, where hemoglobin level measurement is needed for anemia management.

“We are delighted that the excellence of the Hemonitor H1 has been recognized through this procurement project,” said Jeong Jeom-gyu, CEO of GenBody. “We will continue to provide innovative in vitro diagnostic solutions for disease diagnosis and management, further strengthening our global market presence,” he added.

Conversely, GenBody recently passed the technology assessment for KOSDAQ’s technology special listing and plans to submit its preliminary listing review to the Korea Exchange in early 2025, following the release of its 2024 audit report. Korea Investment & Securities is acting as the lead manager for the listing.